<div id="readability-page-1"><p>YD Bio Limited (NASDAQ:YDES - Get Free Report) was up 7.9% during mid-day trading on Monday . The company traded as high as $7.50 and last traded at $7.8770. Approximately 759 shares were traded  during trading, a decline of 98% from the average daily volume of 37,850 shares. The stock had previously closed at $7.30.</p><h2>Analyst Ratings Changes</h2><p>A number of research firms recently issued reports on YDES. Wall Street Zen upgraded YD Bio from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, February 28th. Weiss Ratings  reaffirmed a &#34;sell (d+)&#34; rating on shares of YD Bio in a research report on Monday, December 29th. One investment analyst  has rated the stock with a Sell rating,  According to MarketBeat, the company  has an average rating of &#34;Sell&#34;.</p><p><b>View Our Latest Stock Report on YD Bio</b></p><h2>YD Bio Stock Up 5.7%</h2><p>The stock's 50 day moving average is $10.26. </p><h2>Institutional Trading of YD Bio</h2><p>An institutional investor recently raised its position in YD Bio stock. Geode Capital Management LLC lifted its stake in shares of  YD Bio Limited (NASDAQ:YDES - Free Report) by 10.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 58,363 shares of the biotechnology company's stock after purchasing an additional 5,292 shares during the quarter. Geode Capital Management LLC owned 0.08% of YD Bio worth $711,000 as of its most recent filing with the Securities and Exchange Commission. </p><h2>About YD Bio</h2> (Get Free Report)<p>YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.  </p><h2>Read More</h2><ul><li>Five stocks we like better than YD Bio</li><li>The “secret weapon” behind Microsoft, Meta, Amazon, and Google</li><li>A personal warning from Martin Weiss (Please read)</li><li>Elon Musk: This Could Turn $100 into $100,000</li><li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li><li>Iran isn't the real war</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in YD Bio Right Now?</h2><p>Before you consider YD Bio, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and YD Bio wasn't on the list.</p><p>While YD Bio currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

YDES

<p>YD Bio (NASDAQ:YDES) shares rose 7.9% to $7.8770 during mid-day trading, despite a significant drop in trading volume. Analyst ratings show a mixed outlook, with Wall Street Zen upgrading the stock to a 'hold' while Weiss Ratings maintains a 'sell' rating. Institutional investor Geode Capital Management increased its stake by 10%. The stock's 50-day moving average is $10.26, and it currently holds an average rating of 'sell' among analysts. Investors are advised to consider other stocks recommended by top analysts instead of YD Bio.</p>

YD Bio (NASDAQ:YDES) Trading 7.9% Higher - Still a Buy?